Search

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe mechanobullous disease characterized at the molecular level by mutations in the COL7A1 gene, leading to reduced type VII collagen and defective anchoring fibrils at the dermal–epidermal junction (DEJ) (Fine et al., 2000). Patients who inherit this condition suffer from recurrent blistering, cutaneous ulcers, severe scarring, and deformities, and they are at high risk for developing life-threatening squamous cell carcinoma (Mallipeddi, 2002). Currently, there is no treatment for RDEB.

Advances in phototherapy have led to significant improvement in the care of patients with a variety of skin disorders, ranging from psoriasis to vitiligo. The use of narrow-band ultraviolet radiation B (NB-UVB), with peak fluence at 311 nm, has been one such advance. Superior in efficacy to broad-band UVB (BB-UVB), it combines added efficacy similar to that of photochemotherapy (PUVA), with less inconvenience (van Weelden et al., 1988; Coven et al., 1997; Gathers et al., 2002). However, experimental data suggest that the use of NB-UVB is not without cost. Several investigative studies have determined that NB-UVB possesses greater potential for skin carcinogenesis (Flindt-Hansen et al., 1991; Wulf et al., 1994; Gibbs et al., 1995) than BB-UVB, already a known carcinogen (Kraemer, 1997).